By Josh White
Date: Tuesday 22 Apr 2025
(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for the registration phase of its phase two clinical trial, evaluating savolitinib in Chinese patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinoma.
2024 Annual Report and Notice of AGM | 07-Apr-2025 | 09:30 | RNS |
Extraordinary General Meeting – Poll Results | 31-Mar-2025 | 10:30 | RNS |
Retirement of Independent Non-executive Directors | 20-Mar-2025 | 09:30 | RNS |
2024 Final Results and Business Updates | 19-Mar-2025 | 11:00 | RNS |
Adoption of the 2025 Long Term Incentive Plan | 14-Mar-2025 | 09:30 | RNS |
Chinese medicine firm employs Cambridge Universi... | 23-Dec-2009 | Guardian |
Joint venture offers food for growth | 09-Oct-2009 | The Scotsman |
Chi-Med unveils maiden profit | 31-Jul-2009 | The Scotsman |
Chi-Med happy with drug tests | 14-Jul-2009 | The Scotsman |
'Watershed' year depends on US drugs trial says ... | 17-Mar-2009 | The Scotsman |
Questor: Hutchison China Meditech | 03-Jul-2007 | Telegraph |
The Week Ahead: Wolseley investors seek calm ami... | 19-Mar-2007 | The Independent |
The Investment Column: Hutchison China MediTech | 21-Nov-2006 | The Independent |
Shares That Sound Good | 02-Jun-2006 | Motley Fool UK |
No recent information was found.
Currency | UK Pounds |
Share Price | 225.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 352.00p |
52 Week Low | 189.00p |
Volume | 4,436 |
Shares Issued | 871.60m |
Market Cap | £1,961.10m |
RiskGrade | 226 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:35 | 91 @ 225.00p |
16:35 | 31 @ 225.00p |
16:35 | 30 @ 225.00p |
16:35 | 14 @ 225.00p |
16:35 | 7 @ 225.00p |
You are here: research